Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant either must have ceased lactating at screening or, if still lactating or actively breastfeeding at screening, must agree to temporarily cease giving breast milk to her infant(s)~* Participant has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Axis I Disorders (SCID-I)~* Participant was \<=six months postpartum.~Key Exclusion Criteria:~* Active psychosis~* Attempted suicide associated with current episode of postpartum depression~* Medical history of seizures~* Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.~Note: suicidal ideation was not an exclusion. Other protocol-defined inclusion/exclusion criteria might apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Part A: SAGE-217 15/20 mg Oral Solution (Type: EXPERIMENTAL): Participants received SAGE-217, 15 milligrams (mg), oral solution, twice daily (BID) for first 2 days followed by SAGE-217, 15 or 20 mg, oral solution, BID, starting on Day 3 for up to 14 days as tolerated.
- Part B: Placebo (Type: PLACEBO_COMPARATOR): Participants received SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
- Part B: SAGE 217 30 mg Capsules (Type: EXPERIMENTAL): Participants received SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).